Clinical Trial Update: Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update notes the completion of Phase 1 and Phase 2 studies of oblimersen (Genasense) in patients with relapsed or refractory Waldenström's m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Genasense (oblimersen)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Waldenström Macroglobulinemia | Phase 1, Phase 2 | Status: COMPLETED